RxDoctor Payments Data

Kevin Tucker, MD

Nephrology · Milwaukee, WINPI 1295809036

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,750 of the $14,702 with a category attached, or 66.3%. Exthera Medical Corporation accounts for 66.4% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $7,876, more than ten times the $762 reported in 2019. Among nephrology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,702in general payments, 2019–2025

Across 246 payments — averaging $59.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exthera Medical Corporation$10K
  • Amgen$983
  • AstraZeneca$654
  • Novartis$350
  • Vifor Pharma, Inc.$284
  • Daiichi Sankyo Inc.$259
  • plus $2K from 32 others

What the payments were for

  • Consulting fees$9,75066%
  • Food & beverage$4,82733%
  • Education$1241%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,702 in reported general payments places this provider in the 90th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$196,742
Medicare patients
365
Services billed
1,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban277$85,090
CreonLipase/Protease/Amylase11$40,189
RenvelaSevelamer Carbonate12$23,708
VeltassaPatiromer Calcium Sorbitex11$14,918
TrulicityDulaglutide28$13,757
MyrbetriqMirabegron51$12,475
Midodrine Hcl67$7,579
LinzessLinaclotide12$7,235
XareltoRivaroxaban26$6,374
Pantoprazole Sodium78$6,357
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$6,074
Atorvastatin Calcium291$5,835
Sevelamer Carbonate19$5,488
JardianceEmpagliflozin17$5,036
ShingrixVaricella-Zoster Ge/As01b/Pf21$4,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$85,090277 claims
Sanofi-aventis U.S. LLCRenvela$88$23,70812 claims
Lilly USA, LLCTrulicity$49$13,75728 claims
Boehringer IngelheimJardiance$76$5,03617 claims
GSKShingrix$59$4,47221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →